Apreo Health announces milestones for BREATHE Airway Scaffold technology
The BREATHE-3 clinical trial is a cornerstone, and the team will attend ATS 2026 in Orlando.
See the latest news and media coverage for Apreo Health. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of bronchoscopic treatments for severe emphysema
apreohealth.comLast updated
In short: Apreo Health advanced its BREATHE-3 clinical trial for emphysema, added strategic leadership, and presented device data at the ATS 2026 conference.
The BREATHE-3 clinical trial is a cornerstone, and the team will attend ATS 2026 in Orlando.
The study evaluates new solutions for hyperinflation from severe emphysema advancing respiratory care.
The study evaluates minimally invasive options for severe emphysema at University of Pittsburgh.
The trial aims to reduce lung hyperinflation and improve breathing for emphysema patients.
The trial’s first patient has been treated to assess the BREATHE Airway Scaffold, which was developed to enhance breathing and daily functioning in patients with...
The Phase-3 trial of Apreo Health’s bronchoscopic airway scaffold for severe emphysema and hyperinflation is now enrolling at the Temple Lung Center.
California-based startup Apreo Health has raised $130m to further the development of its implant for treating severe emphysema. The Series B round was co-led by...
Company emerges from stealth with a new class of interventional therapy designed to expand access to treatment for severe emphysema MENLO PARK, Calif., May 13...
Track Apreo Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.